Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 532 articles:
HTML format



Single Articles


    November 2021
  1. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    PubMed    


  2. NJOKU K, Ramchander NC, Wan YL, Barr CE, et al
    Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
    Gynecol Oncol. 2021 Nov 18. pii: S0090-8258(21)01602.
    PubMed     Abstract available


  3. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    PubMed     Abstract available


  4. HUANG J, Deng Y, Boakye D, Tin MS, et al
    Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01598.
    PubMed     Abstract available


  5. LADBURY C, Li R, Shiao J, Liu J, et al
    Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?
    Gynecol Oncol. 2021 Nov 15. pii: S0090-8258(21)01600.
    PubMed     Abstract available


  6. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    PubMed     Abstract available


  7. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    PubMed     Abstract available


  8. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    PubMed     Abstract available


  9. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    PubMed     Abstract available


  10. PRAISS AM, Huang Y, St Clair CM, Melamed A, et al
    Long-term outcomes of vaginal hysterectomy for endometrial cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01526.
    PubMed     Abstract available


  11. SISODIA RC, Alimena S, Ferris W, Saini A, et al
    Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01528.
    PubMed     Abstract available


  12. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    PubMed     Abstract available


  13. ORELLANA TJ, Kim H, Beriwal S, Bhargava R, et al
    Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01515.
    PubMed     Abstract available


  14. MENG Y, Chu T, Lin S, Wu P, et al
    Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01451.
    PubMed     Abstract available


  15. ALHILLI MM, Arend RC
    International gynecologic cancer society (IGCS) 2021 meeting report.
    Gynecol Oncol. 2021 Nov 1. pii: S0090-8258(21)01548.
    PubMed    


  16. HINCHCLIFF EM, Westin SN
    Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
    Gynecol Oncol. 2021;163:217-219.
    PubMed    


    October 2021
  17. MATSUO K, Klar M, Khetan VU, Violette CJ, et al
    Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States.
    Gynecol Oncol. 2021 Oct 30. pii: S0090-8258(21)01529.
    PubMed     Abstract available


  18. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    PubMed     Abstract available


  19. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    PubMed     Abstract available


  20. WARRING SK, Borah B, Moriarty J, Gullerud R, et al
    The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01523.
    PubMed     Abstract available


  21. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    PubMed     Abstract available


  22. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    PubMed     Abstract available


  23. CHARGARI C, Arbyn M, Leary A, Abu-Rustum NR, et al
    Increasing global accessibility to high-level treatments for cervical cancers.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01517.
    PubMed     Abstract available


  24. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    PubMed     Abstract available


  25. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    PubMed     Abstract available


  26. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    PubMed     Abstract available


  27. BALAYA V, Guani B, Morice P, Querleu D, et al
    Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01518.
    PubMed     Abstract available


  28. SHIN W, Park SY, Seo SS, Lim MC, et al
    Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01514.
    PubMed     Abstract available


  29. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    PubMed     Abstract available


  30. GUDGEON JM, Wallentine JC, Bonham EM, McLaughlin HD, et al
    Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial.
    Gynecol Oncol. 2021 Oct 21. pii: S0090-8258(21)01401.
    PubMed     Abstract available


  31. HE WQ, Li C
    Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends.
    Gynecol Oncol. 2021 Oct 20. pii: S0090-8258(21)01519.
    PubMed     Abstract available


  32. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    PubMed    


  33. HOROWITZ NS, Eskander RN, Adelman MR, Burke W, et al
    Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01421.
    PubMed    


  34. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    PubMed     Abstract available


  35. MARTIN A, Wells A, Anderson ML, Chern JY, et al
    Trends in ureteral surgery on an academic gynecologic oncology service.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01453.
    PubMed     Abstract available


  36. THOMAIER L, Darst BF, Jewett P, Hoffmann C, et al
    Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01450.
    PubMed     Abstract available


  37. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].
    Gynecol Oncol. 2021 Oct 12. pii: S0090-8258(21)01386.
    PubMed    


  38. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    PubMed     Abstract available


  39. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    PubMed     Abstract available


  40. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    PubMed     Abstract available


  41. EDMONDSON RJ, O'Connell RL, Banerjee S, Mileshkin L, et al
    Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Oct 5. pii: S0090-8258(21)01379.
    PubMed     Abstract available


  42. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    PubMed     Abstract available


  43. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    PubMed     Abstract available


  44. LEE L, Howitt B, Cheng T, King M, et al
    MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01384.
    PubMed     Abstract available


  45. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    PubMed    


  46. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    PubMed    


    September 2021
  47. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    PubMed     Abstract available


  48. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    PubMed     Abstract available


  49. HOEIJMAKERS YM, Eysbouts YK, Massuger LFAG, Dandis R, et al
    Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01385.
    PubMed     Abstract available


  50. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    PubMed     Abstract available


  51. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    PubMed     Abstract available


  52. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01393.
    PubMed    


  53. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    PubMed     Abstract available


  54. VAN DER PLAS RCJ, Bos AME, Jurgenliemk-Schulz IM, Gerestein CG, et al
    Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
    Gynecol Oncol. 2021 Sep 25. pii: S0090-8258(21)01334.
    PubMed     Abstract available


  55. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    PubMed     Abstract available


  56. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    PubMed     Abstract available


  57. CONTOS G, Baca Y, Xiu J, Brown J, et al
    Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Gynecol Oncol. 2021 Sep 22. pii: S0090-8258(21)01380.
    PubMed     Abstract available


  58. JOU J, Charo L, Hom-Tedla M, Coakley K, et al
    Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01374.
    PubMed     Abstract available


  59. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    PubMed     Abstract available


  60. HUANG T, Townsend MK, Dood RL, Sood AK, et al
    Antihypertensive medication use and ovarian cancer survival.
    Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
    PubMed     Abstract available


  61. WENZEL L, Huang HQ, Cella D, McKinney CO, et al
    Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
    PubMed     Abstract available


  62. COBB LP, Siamakpour-Reihani S, Zhang D, Qin X, et al
    Obesity and altered angiogenic-related gene expression in endometrial cancer.
    Gynecol Oncol. 2021 Sep 15. pii: S0090-8258(21)01308.
    PubMed     Abstract available


  63. POZZAR RA, Hammer MJ, Paul SM, Cooper BA, et al
    Distinct sleep disturbance profiles among patients with gynecologic cancer receiving chemotherapy.
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01333.
    PubMed     Abstract available


  64. GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
    Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
    PubMed     Abstract available


  65. STRAUBHAR AM, Chi AJ, Zhou QC, Iasonos A, et al
    Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
    Gynecol Oncol. 2021 Sep 10. pii: S0090-8258(21)01331.
    PubMed     Abstract available


  66. SOMASEGAR S, Hoppenot C, Kuchta K, Sereika A, et al
    Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01325.
    PubMed     Abstract available


  67. MOSS HA, Chen L, Hershman DL, Davidson B, et al
    Adherence to PARP inhibitor therapy among women with ovarian cancer.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
    PubMed     Abstract available


  68. LUHRS O, Ekdahl L, Geppert B, Lonnerfors C, et al
    Resection of the upper paracervical lymphovascular tissue should be an integral part of a pelvic sentinel lymph node algorithm in early stage cervical cancer.
    Gynecol Oncol. 2021 Sep 8. pii: S0090-8258(21)01328.
    PubMed     Abstract available


  69. WANG Z, Guo E, Yang B, Xiao R, et al
    Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
    PubMed     Abstract available


  70. QIN J, Shahangian S, Saraiya M, Holt H, et al
    Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01321.
    PubMed     Abstract available


  71. WU S, Ding X, Kong Y, Acharya S, et al
    The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females.
    Gynecol Oncol. 2021 Sep 6. pii: S0090-8258(21)01314.
    PubMed     Abstract available


  72. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
    From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?
    Gynecol Oncol. 2021 Sep 6. pii: S0090-8258(21)01324.
    PubMed     Abstract available


  73. WERNER B, Yuwono N, Duggan J, Liu D, et al
    Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Gynecol Oncol. 2021;162:720-727.
    PubMed     Abstract available


  74. VENKAT P, Salani R
    Changing paradigms in intermediate-risk cervical cancer: Sedlis revisited.
    Gynecol Oncol. 2021;162:527-528.
    PubMed    


  75. CAMPBELL R, King MT, Ross TL, Cohen PA, et al
    Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
    Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
    PubMed     Abstract available


    August 2021
  76. FUH KC, Bookman MA, Liu JF, Coleman RL, et al
    Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
    PubMed     Abstract available


  77. ACKROYD SA, Shih YT, Kim B, Lee NK, et al
    A look at the gynecologic oncologist workforce - Are we meeting patient demand?
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01311.
    PubMed     Abstract available


  78. STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
    Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
    PubMed     Abstract available


  79. EBINA Y, Yamagami W, Kobayashi Y, Tabata T, et al
    Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01310.
    PubMed     Abstract available


  80. MATZ M, Weir HK, Alkhalawi E, Coleman MP, et al
    Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3).
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01312.
    PubMed     Abstract available


  81. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
    PubMed     Abstract available


  82. TAMURA R, Yoshihara K, Matsuo K, Yachida N, et al
    Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01307.
    PubMed     Abstract available


  83. SOMASEGAR S, Weiss AS, Norquist BM, Khasnavis N, et al
    Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01315.
    PubMed     Abstract available


  84. TYMON-ROSARIO J, Bonazzoli E, Bellone S, Manzano A, et al
    DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01313.
    PubMed     Abstract available


  85. O'MALLEY DM, Oaknin A, Monk BJ, Selle F, et al
    Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01316.
    PubMed     Abstract available


  86. D'AMORA P, Silva IDCG, Tewari KS, Bristow RE, et al
    Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)00646.
    PubMed     Abstract available


  87. MANNING-GEIST BL, Gatius S, Liu Y, Gil M, et al
    Diagnosis and management of an endometrial cancer patient with Cowden syndrome.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01292.
    PubMed     Abstract available


  88. D'ALESSANDRIS N, Travaglino A, Santoro A, Arciuolo D, et al
    TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01309.
    PubMed     Abstract available


  89. COWAN M, Swetzig WM, Adorno-Cruz V, Pineda MJ, et al
    Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecol Oncol. 2021 Aug 18. pii: S0090-8258(21)00650.
    PubMed     Abstract available


  90. BANERJEE SN, Tang M, O'Connell RL, Sjoquist K, et al
    A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
    Gynecol Oncol. 2021 Aug 16. pii: S0090-8258(21)00586.
    PubMed     Abstract available


  91. HUEPENBECKER SP, Iniesta MD, Zorrilla-Vaca A, Ramirez PT, et al
    Incidence of acute kidney injury after open gynecologic surgery in an enhanced recovery after surgery pathway.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00651.
    PubMed     Abstract available


  92. LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
    Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
    PubMed     Abstract available


  93. PARK M, Lim J, Lee JA, Park HJ, et al
    Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
    Gynecol Oncol. 2021 Aug 12. pii: S0090-8258(21)00645.
    PubMed     Abstract available


  94. WU Y, Huang J, Ivan C, Sun Y, et al
    MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00648.
    PubMed     Abstract available


  95. WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
    PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
    PubMed    


  96. AREND RC, Goel N, Roane BM, Foxall ME, et al
    Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
    Gynecol Oncol. 2021 Aug 6. pii: S0090-8258(21)00579.
    PubMed     Abstract available


  97. TYMON-ROSARIO J, Siegel ER, Bellone S, Harold J, et al
    Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
    Gynecol Oncol. 2021 Aug 6. pii: S0090-8258(21)00599.
    PubMed     Abstract available


  98. WENTZENSEN N, O'Brien KM
    Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
    Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
    PubMed     Abstract available


  99. COLOMBO N, Moore K, Scambia G, Oaknin A, et al
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
    PubMed     Abstract available


  100. GREEN AK, Makker V
    Novel therapy in endometrial cancer: How much will we pay?
    Gynecol Oncol. 2021;162:243-244.
    PubMed    


    July 2021
  101. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
    Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
    PubMed    


  102. HRUDA M, Robova H, Rob L, Halaska MJ, et al
    Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Oncological outcomes.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00593.
    PubMed     Abstract available


  103. VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
    Ambient air pollution and ovarian cancer survival in California.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
    PubMed     Abstract available


  104. NANEZ A, Stram DA, Garcia C, Powell CB, et al
    Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
    PubMed     Abstract available


  105. PARK AB, Darcy KM, Tian C, Casablanca Y, et al
    Racial disparities in survival among women with endometrial cancer in an equal access system.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00584.
    PubMed     Abstract available


  106. LAZURKO C, Clark M, Pulman K, Lennox G, et al
    Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
    PubMed     Abstract available


  107. MARCHETTI C, Rosati A, De Felice F, Boccia SM, et al
    Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00587.
    PubMed     Abstract available


  108. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00591.
    PubMed     Abstract available


  109. BASARAN D, Boerner T, Suhner J, Sassine D, et al
    Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
    PubMed     Abstract available


  110. TIWARI R, Narayanan GS, Reddy VP, Vishwanathan B, et al
    Impact of nodal boost irradiation and MR-based brachytherapy on oncologic outcomes in node-positive cervical cancer.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00585.
    PubMed     Abstract available


  111. EOH KJ, Park EY, Chang YJ, Ha HI, et al
    The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
    PubMed     Abstract available


  112. MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
    Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
    PubMed     Abstract available


  113. CIBULA D, Rob L, Mallmann P, Knapp P, et al
    Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
    PubMed     Abstract available


  114. AVIKI EM, Schleicher SM, Boyd L, Liang M, et al
    The oncology care model and the future of alternative payment models: A gynecologic oncology perspective.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00576.
    PubMed    


  115. DE NONNEVILLE A, Zemmour C, Frank S, Joly F, et al
    Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00581.
    PubMed     Abstract available


  116. MURAKAMI N, Ando K, Murata M, Murata K, et al
    Why not de-intensification for uterine cervical cancer?
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00583.
    PubMed     Abstract available


  117. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    PubMed     Abstract available


  118. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    PubMed     Abstract available


  119. GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
    Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
    PubMed     Abstract available


  120. ZONG L, Sun Z, Mo S, Lu Z, et al
    PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00539.
    PubMed     Abstract available


  121. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    PubMed     Abstract available


  122. BACKES FJ, Wei L, Chen M, Hill K, et al
    Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
    PubMed     Abstract available


  123. TRAVAGLINO A, Raffone A, Santoro A, Raimondo D, et al
    Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00537.
    PubMed     Abstract available


  124. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    PubMed     Abstract available


  125. POLI JG, Paiva G, Freitas F, Mora P, et al
    Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00551.
    PubMed     Abstract available


  126. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    PubMed     Abstract available


  127. KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
    The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
    PubMed     Abstract available


  128. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    PubMed     Abstract available


  129. HAESEN J, Salihi R, Van Gorp T, Van Nieuwenhuysen E, et al
    Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00522.
    PubMed     Abstract available


  130. VICTOOR J, Borght SV, Spans L, Lehnert S, et al
    Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00527.
    PubMed     Abstract available


  131. SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
    Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
    PubMed     Abstract available


  132. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    PubMed     Abstract available


  133. GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
    Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
    PubMed     Abstract available


  134. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    PubMed     Abstract available


  135. HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
    Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
    PubMed     Abstract available


  136. STRAUBHAR AM, Dalton L, Rolston A, McCool K, et al
    Optimization of postoperative opioid prescriptions in gynecologic oncology: Striking a balance between opioid reduction and pain control.
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00519.
    PubMed     Abstract available


  137. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
    Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial).
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00512.
    PubMed     Abstract available


    June 2021
  138. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00511.
    PubMed     Abstract available


  139. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    PubMed     Abstract available


  140. FEIGENBERG T, Cormier B, Gotlieb WH, Jegatheeswaran K, et al
    Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology (GOC) community of practice (CoP).
    Gynecol Oncol. 2021 Jun 25. pii: S0090-8258(21)00493.
    PubMed     Abstract available


  141. JIA N, Che X, Jiang Y, Zhu M, et al
    Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 25. pii: S0090-8258(21)00495.
    PubMed     Abstract available


  142. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    PubMed     Abstract available


  143. GRAY HJ, Secord AA
    Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care.
    Gynecol Oncol. 2021 Jun 21. pii: S0090-8258(21)00332.
    PubMed    


  144. WRIGHT JD, Huang Y, Melamed A, Albright BB, et al
    Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
    Gynecol Oncol. 2021 Jun 19. pii: S0090-8258(21)00496.
    PubMed     Abstract available


  145. BARRINGTON DA, Haight PJ, Calhoun C, Tubbs C, et al
    Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00494.
    PubMed     Abstract available


  146. ZHANG G, Zhang Y, He F, Wu H, et al
    Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors.
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00492.
    PubMed     Abstract available


  147. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
    Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
    PubMed     Abstract available


  148. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    PubMed     Abstract available


  149. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    PubMed     Abstract available


  150. YUAN R, Zhang C, Li Q, Ji M, et al
    The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis.
    Gynecol Oncol. 2021 Jun 14. pii: S0090-8258(21)00488.
    PubMed     Abstract available


  151. ZAMORANO AS, Wilson EM, Liu J, Leon A, et al
    Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial.
    Gynecol Oncol. 2021 Jun 14. pii: S0090-8258(21)00487.
    PubMed     Abstract available


  152. IMBODEN S, Nastic D, Ghaderi M, Rydberg F, et al
    Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
    Gynecol Oncol. 2021 Jun 11. pii: S0090-8258(21)00432.
    PubMed     Abstract available


  153. BENITO V, Lubrano A, Perez-Regadera JF, Torne A, et al
    Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00485.
    PubMed     Abstract available


  154. FAN Y, Zhang YF, Wang MY, Mu Y, et al
    Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
    PubMed     Abstract available


  155. MATANES E, Eisenberg N, Lau S, Salvador S, et al
    Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00446.
    PubMed     Abstract available


  156. RONSINI C, Anchora LP, Restaino S, Fedele C, et al
    The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00482.
    PubMed     Abstract available


  157. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
    PubMed     Abstract available


  158. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    PubMed     Abstract available


  159. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    PubMed     Abstract available


  160. ACKROYD SA, Huang ES, Kurnit KC, Lee NK, et al
    Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Gynecol Oncol. 2021 Jun 5. pii: S0090-8258(21)00444.
    PubMed     Abstract available


  161. DOSSUS L, Kouloura E, Biessy C, Viallon V, et al
    Prospective analysis of circulating metabolites and endometrial cancer risk.
    Gynecol Oncol. 2021 Jun 5. pii: S0090-8258(21)00447.
    PubMed     Abstract available


  162. JOU J, Brodsky A, Charo L, Binder P, et al
    Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials.
    Gynecol Oncol. 2021 Jun 4. pii: S0090-8258(21)00443.
    PubMed     Abstract available


  163. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    PubMed     Abstract available


  164. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    PubMed     Abstract available


  165. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    PubMed     Abstract available


  166. MILLS JM, Morgan JR, Dhaliwal A, Perkins RB, et al
    Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00441.
    PubMed     Abstract available


  167. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    PubMed     Abstract available


  168. MOUKARZEL LA, Braxton KF, Zhou QC, Pedra Nobre S, et al
    Non-exenterative surgical management of recurrent endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00426.
    PubMed     Abstract available


  169. RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
    Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00435.
    PubMed     Abstract available


  170. SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
    Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
    PubMed     Abstract available


  171. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    PubMed     Abstract available


    May 2021
  172. SERT BM, Kristensen GB, Kleppe A, Dorum A, et al
    Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.
    Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00434.
    PubMed     Abstract available


  173. CHAMBERS LM, Chalif J, Yao M, Chichura A, et al
    Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00409.
    PubMed     Abstract available


  174. BRODEUR MN, Dejean R, Beauchemin MC, Samouelian V, et al
    Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00429.
    PubMed     Abstract available


  175. SONG F, Belinson JL, Yan P, Huang X, et al
    Evaluation of p16(INK4a) immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00410.
    PubMed     Abstract available


  176. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    PubMed     Abstract available


  177. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    PubMed     Abstract available


  178. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    PubMed     Abstract available


  179. JANDA M, Robledo KP, Gebski V, Armes JE, et al
    Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151].
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00422.
    PubMed    


  180. MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
    Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
    PubMed     Abstract available


  181. TOBONI MD, Crane EK, Brown J, Shushkevich A, et al
    State of the science: Uterine carcinosarcomas: From pathology to practice.
    Gynecol Oncol. 2021 May 21. pii: S0090-8258(21)00362.
    PubMed     Abstract available


  182. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    PubMed     Abstract available


  183. WINER I, Kim C, Gehrig P
    Neuroendocrine tumors of the gynecologic tract update.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00359.
    PubMed    


  184. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    PubMed     Abstract available


  185. ISHIKAWA M, Shibata T, Iwata T, Nishio S, et al
    A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Prim
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00403.
    PubMed     Abstract available


  186. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    PubMed     Abstract available


  187. TRAN DT, Vo VK, Le MT, Chuang L, et al
    Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
    PubMed     Abstract available


  188. MATSUO K, Mandelbaum RS, Klar M, Ciesielski KM, et al
    Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00364.
    PubMed     Abstract available


  189. CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
    Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
    PubMed     Abstract available


  190. ZAMMARRELLI WA 3RD, Afonso AM, Broach V, Sonoda Y, et al
    Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00405.
    PubMed     Abstract available


  191. MCALARNEN LA, Tsaih SW, Aliani R, Simske NM, et al
    Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum.
    Gynecol Oncol. 2021 May 11. pii: S0090-8258(21)00357.
    PubMed     Abstract available


  192. GONZALEZ R, Kurtovic K, Habib AS, Ryan ES, et al
    A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service.
    Gynecol Oncol. 2021 May 11. pii: S0090-8258(21)00355.
    PubMed     Abstract available


  193. FUCINARI J, Elshaikh MA, Ruterbusch JJ, Khalil R, et al
    The impact of race, comorbid conditions and obesity on survival endpoints in women with high grade endometrial carcinoma.
    Gynecol Oncol. 2021 May 10. pii: S0090-8258(21)00356.
    PubMed     Abstract available


  194. HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
    What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
    PubMed     Abstract available


  195. JEONG SY, Cho YJ, Ryu JY, Choi JJ, et al
    Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00348.
    PubMed     Abstract available


  196. CAO L, Wei M, Liu Y, Fu J, et al
    Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
    PubMed     Abstract available


  197. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    PubMed     Abstract available


  198. BAGARIA M, Wentzensen N, Clarke M, Hopkins MR, et al
    Quantifying procedural pain associated with office gynecologic tract sampling methods.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00353.
    PubMed     Abstract available


  199. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    PubMed     Abstract available


  200. HOW JA, Patel S, Fellman B, Lu KH, et al
    Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00354.
    PubMed     Abstract available


  201. SIMS TT, Boruta DM
    Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
    Gynecol Oncol. 2021;161:331-332.
    PubMed    


  202. AIOB A, Naskovica K, Sharon A, Bornstein J, et al
    A possible association between hydatidiform mole and the COVID-19 pandemic: A retrospective cohort study.
    Gynecol Oncol. 2021;161:454-457.
    PubMed     Abstract available


  203. PRIESKE K, Woelber L, Muallem MZ, Eulenburg C, et al
    Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2021;161:442-448.
    PubMed     Abstract available


  204. BOHLIN KS, Bruno AK, von Knorring C, Rahm C, et al
    Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study.
    Gynecol Oncol. 2021;161:449-453.
    PubMed     Abstract available


  205. KOUAL M, Benoit L, Nguyen-Xuan HT, Bentivegna E, et al
    Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review.
    Gynecol Oncol. 2021;161:436-441.
    PubMed     Abstract available


  206. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    PubMed     Abstract available


    April 2021
  207. SUN Z, Wang S, Yang R, Li X, et al
    Gestational diabetes mellitus and risks of gynecologic cancers: Results from a nationwide Swedish twin study.
    Gynecol Oncol. 2021 Apr 29. pii: S0090-8258(21)00266.
    PubMed     Abstract available


  208. BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
    Uterine serous carcinoma.
    Gynecol Oncol. 2021 Apr 29. pii: S0090-8258(21)00349.
    PubMed     Abstract available


  209. PIEDIMONTE S, Li S, Laframboise S, Ferguson SE, et al
    Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center.
    Gynecol Oncol. 2021 Apr 28. pii: S0090-8258(21)00350.
    PubMed     Abstract available


  210. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    PubMed     Abstract available


  211. DILLEY S, Huh W, Blechter B, Rositch AF, et al
    It's time to re-evaluate cervical Cancer screening after age 65.
    Gynecol Oncol. 2021 Apr 26. pii: S0090-8258(21)00347.
    PubMed     Abstract available


  212. MARAMAI M, Achilarre MT, Aloisi A, Betella I, et al
    Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2021 Apr 24. pii: S0090-8258(21)00346.
    PubMed     Abstract available


  213. KASUGA Y, Ikenoue S, Tanaka M, Ochiai D, et al
    Management of pregnancy after radical trachelectomy.
    Gynecol Oncol. 2021 Apr 23. pii: S0090-8258(21)00343.
    PubMed     Abstract available


  214. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    PubMed     Abstract available


  215. RUBINSTEIN MM, Dickinson S, Narayan P, Zhou Q, et al
    Bevacizumab in advanced endometrial cancer.
    Gynecol Oncol. 2021 Apr 21. pii: S0090-8258(21)00326.
    PubMed     Abstract available


  216. LUCCHINI SM, Esteban A, Nigra MA, Palacios AT, et al
    Updates on conservative management of endometrial cancer in patients younger than 45 years.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00327.
    PubMed     Abstract available


  217. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    PubMed     Abstract available


  218. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    PubMed     Abstract available


  219. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    PubMed     Abstract available


  220. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    PubMed     Abstract available


  221. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    PubMed     Abstract available


  222. SHIM SH, Chae SH, So KA, Lee SJ, et al
    Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
    PubMed     Abstract available


  223. GONZALEZ-BOSQUET J, Bakkum-Gamez JN, Weaver AL, McGree ME, et al
    PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00318.
    PubMed     Abstract available


  224. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    PubMed     Abstract available


  225. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Erratum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00319.
    PubMed    


  226. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    PubMed     Abstract available


  227. HUTTEN RJ, Huang YJ, Gaffney DK
    Stereotactic body radiotherapy for the treatment of gynecologic malignancies: Passing fancy or here to stay?
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00320.
    PubMed    


  228. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    PubMed     Abstract available


  229. VREDE SW, van Weelden WJ, Visser NCM, Bulten J, et al
    Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00269.
    PubMed     Abstract available


  230. FANG C, Zhang P, Yu A, Yang Y, et al
    Different prognosis of stage IIIB cervical cancer patients with lower third of vaginal invasion and those without.
    Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00275.
    PubMed     Abstract available


  231. VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
    The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
    PubMed     Abstract available


  232. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: Results from an Australian record-linkage study.
    Gynecol Oncol. 2021 Apr 9. pii: S0090-8258(21)00271.
    PubMed     Abstract available


  233. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    PubMed     Abstract available


  234. JANDA M, Robledo KP, Gebski V, Armes JE, et al
    Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
    Gynecol Oncol. 2021;161:143-151.
    PubMed     Abstract available


  235. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    PubMed     Abstract available


  236. DODD RH, Cvejic E, Bell K, Black K, et al
    Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study.
    Gynecol Oncol. 2021;161:179-187.
    PubMed     Abstract available


  237. BOER FL, Ten Eikelder MLG, van Geloven N, Kapiteijn EH, et al
    Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice.
    Gynecol Oncol. 2021;161:202-210.
    PubMed     Abstract available


  238. CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
    Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
    Gynecol Oncol. 2021;161:282-290.
    PubMed     Abstract available


  239. ASHMORE S, Crafton SM, Miller EM, Krivak TC, et al
    Optimal overall treatment time for adjuvant therapy for women with completely resected, node-positive vulvar cancer.
    Gynecol Oncol. 2021;161:63-69.
    PubMed     Abstract available


  240. JOU J, Zimmer Z, Charo L, Yau C, et al
    HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
    Gynecol Oncol. 2021;161:25-33.
    PubMed     Abstract available


    March 2021
  241. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    PubMed     Abstract available


  242. RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
    Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
    PubMed     Abstract available


  243. GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
    Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
    PubMed     Abstract available


  244. SIA TY, Huang Y, Gockley A, Melamed A, et al
    Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma.
    Gynecol Oncol. 2021 Mar 30. pii: S0090-8258(21)00265.
    PubMed     Abstract available


  245. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    PubMed     Abstract available


  246. HAN Y, Park IS, Kim SI, Wang W, et al
    Increasing serum gamma-glutamyltransferase level accompanies a rapid increase in the incidence of endometrial cancer in Korea: A nationwide cohort study.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00262.
    PubMed     Abstract available


  247. RAHIMIAN N, Razavi ZS, Aslanbeigi F, Mirkhabbaz AM, et al
    Non-coding RNAs related to angiogenesis in gynecological cancer.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00258.
    PubMed     Abstract available


  248. FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
    Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
    PubMed     Abstract available


  249. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    PubMed     Abstract available


  250. ZHANG X, Devins K, Ko EM, Reyes MC, et al
    Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
    PubMed     Abstract available


  251. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    PubMed     Abstract available


  252. WATSON CH, Puechl AM, Lim S, Monuszko K, et al
    Chemotherapy discontinuation processes in a gynecologic oncology population.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00196.
    PubMed     Abstract available


  253. NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
    Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
    PubMed     Abstract available


  254. MATSUO K, Huang Y, Matsuzaki S, Ragab OM, et al
    Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00171.
    PubMed     Abstract available


  255. CHANG CL, Ho SC, Su YF, Juan YC, et al
    DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
    Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00148.
    PubMed     Abstract available


  256. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Corrigendum to 'Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary' [Gynecologic Oncology 157 (2020) 85-88].
    Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00201.
    PubMed    


  257. KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
    Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
    PubMed     Abstract available


  258. ALHOLM Z, Monk BJ, Ting J, Pulgar S, et al
    Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
    Gynecol Oncol. 2021 Mar 16. pii: S0090-8258(21)00194.
    PubMed     Abstract available


  259. SOLSKY I, Chen J, Rebbeck TR
    Corrigendum to "Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations" [Gynecologic Oncology 156 (2020) 363-376].
    Gynecol Oncol. 2021 Mar 14. pii: S0090-8258(21)00200.
    PubMed    


  260. MATSUO K, Klar M, Harter P, Miller H, et al
    Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States.
    Gynecol Oncol. 2021 Mar 13. pii: S0090-8258(21)00232.
    PubMed     Abstract available


  261. MONK BJ, Coleman RL, Herzog TJ, Moore KN, et al
    The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00230.
    PubMed     Abstract available


  262. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    PubMed    


  263. ABEL MK, Liao CI, Chan C, Lee D, et al
    Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00197.
    PubMed     Abstract available


  264. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    PubMed     Abstract available


  265. RAFFONE A, Travaglino A, Raimondo D, Boccellino MP, et al
    Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00175.
    PubMed     Abstract available


  266. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    PubMed     Abstract available


  267. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    PubMed     Abstract available


  268. COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
    Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
    PubMed     Abstract available


  269. SANTORO A, Angelico G, Travaglino A, Raffone A, et al
    Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00174.
    PubMed     Abstract available


  270. POST CCB, Mens JWM, Haverkort MAD, Koppe F, et al
    Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00198.
    PubMed     Abstract available


  271. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    PubMed     Abstract available


  272. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    PubMed     Abstract available


  273. TEOH D, Hill EK, Goldsberry W, Levine L, et al
    Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.
    Gynecol Oncol. 2021 Mar 8. pii: S0090-8258(21)00083.
    PubMed    


  274. SCHNARR KL, Seow H, Elit LM, Pond GR, et al
    The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?
    Gynecol Oncol. 2021 Mar 6. pii: S0090-8258(21)00166.
    PubMed     Abstract available


  275. ULLRICH A, Gultekin M, Teguete I, Trimble EL, et al
    Gynecologic oncology on the global health agenda: A wake-up call.
    Gynecol Oncol. 2021 Mar 5. pii: S0090-8258(21)00178.
    PubMed    


  276. BACKES FJ, Felix AS, Plante M, Gregoire J, et al
    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
    PubMed     Abstract available


  277. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    PubMed     Abstract available


  278. FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
    Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
    PubMed     Abstract available


  279. FELIX AS, Sherman ME
    Implications of the obesity epidemic for endometrial cancer risk, mortality, and survivorship.
    Gynecol Oncol. 2021;160:643-645.
    PubMed    


  280. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    PubMed     Abstract available


  281. KIM J, Cho Y, Kim N, Chung SY, et al
    Magnetic resonance imaging-based validation of the 2018 FIGO staging system in patients treated with definitive radiotherapy for locally advanced cervix cancer.
    Gynecol Oncol. 2021;160:735-741.
    PubMed     Abstract available


    February 2021
  282. BERNARD L, Kwon JS, Simpson AN, Ferguson SE, et al
    The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study.
    Gynecol Oncol. 2021 Feb 26. pii: S0090-8258(21)00165.
    PubMed     Abstract available


  283. MULLEN MM, McKinnish TR, Fiala MA, Zamorano AS, et al
    A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Feb 26. pii: S0090-8258(21)00172.
    PubMed     Abstract available


  284. SIA TY, Wen T, Cham S, Friedman AM, et al
    The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial Cancer surgery.
    Gynecol Oncol. 2021 Feb 24. pii: S0090-8258(21)00167.
    PubMed     Abstract available


  285. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    PubMed     Abstract available


  286. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    PubMed     Abstract available


  287. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    PubMed     Abstract available


  288. DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
    Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
    PubMed     Abstract available


  289. SKORSTENGAARD M, Frederiksen ME, Baillet MV, Beau AB, et al
    Cervical cancer survivors and health care use: A Danish population-based register study.
    Gynecol Oncol. 2021 Feb 19. pii: S0090-8258(21)00139.
    PubMed     Abstract available


  290. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    PubMed     Abstract available


  291. FABER MT, Sperling CD, Bennetsen AKK, Aalborg GL, et al
    A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00147.
    PubMed     Abstract available


  292. FRIEDLANDER M, Benson C, O'Connell RL, Reed N, et al
    Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00153.
    PubMed     Abstract available


  293. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    PubMed     Abstract available


  294. LUO LY, Aviki EM, Lee A, Kollmeier MA, et al
    Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 14. pii: S0090-8258(21)00101.
    PubMed     Abstract available


  295. HICKEY M, Moss KM, Brand A, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
    PubMed     Abstract available


  296. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    PubMed     Abstract available


  297. BURG LC, Vermeulen RJ, Bekkers RLM, Wijn SRW, et al
    A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancer.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00095.
    PubMed     Abstract available


  298. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    PubMed     Abstract available


  299. HASHEMIPOUR M, Boroumand H, Mollazadeh S, Tajiknia V, et al
    Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00140.
    PubMed     Abstract available


  300. INSIN P, Vitoopinyoparb K, Thadanipon K, Charakorn C, et al
    Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: A systematic review and network meta-analysis.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00087.
    PubMed     Abstract available


  301. VARELA CAGETTI L, Gonzague-Casabianca L, Zemmour C, Lambaudie E, et al
    The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00094.
    PubMed     Abstract available


  302. SIEDEL JH, Ring KL, Hu W, Dood RL, et al
    Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(20)34181.
    PubMed     Abstract available


  303. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
    Gynecol Oncol. 2021 Feb 5. pii: S0090-8258(21)00092.
    PubMed    


  304. LATIF N, Oh J, Brensinger C, Morgan M, et al
    Lymphadenectomy is associated with an increased risk of postoperative venous thromboembolism in early stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00090.
    PubMed     Abstract available


  305. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    PubMed     Abstract available


  306. GU B, Shang X, Yan M, Li X, et al
    Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00096.
    PubMed     Abstract available


  307. RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
    Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
    PubMed     Abstract available


  308. ESSELEN KM, Stack-Dunnbier H, Gompers A, Hacker MR, et al
    Crowdsourcing to measure financial toxicity in gynecologic oncology.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00100.
    PubMed     Abstract available


  309. COLEMAN RL, Hu W, Soliman P, Nick A, et al
    Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00082.
    PubMed     Abstract available


  310. TAKENAKA M, Kamii M, Iida Y, Yanaihara N, et al
    Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00054.
    PubMed     Abstract available


  311. KUROKI LM, Morris DH, Greenwade M, Landon M, et al
    Impact of employment and insurance status on distress in gynecologic oncology patients.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00098.
    PubMed     Abstract available


  312. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    PubMed     Abstract available


  313. LESLIE KK, Filiaci VL, Mallen AR, Thiel KW, et al
    Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
    Gynecol Oncol. 2021 Feb 1. pii: S0090-8258(21)00085.
    PubMed     Abstract available


  314. BROOKS SE, Davis EC, Farley JH
    Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair.
    Gynecol Oncol. 2021;160:361-363.
    PubMed    


    January 2021
  315. WANG XS, Kamal M, Chen TH, Shi Q, et al
    Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00081.
    PubMed     Abstract available


  316. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    PubMed     Abstract available


  317. MCGINNIS JM, Jones R, Hillis C, Kokus H, et al
    A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre.
    Gynecol Oncol. 2021 Jan 29. pii: S0090-8258(21)00061.
    PubMed     Abstract available


  318. HAMILTON CA, Pothuri B, Arend RC, Backes FJ, et al
    Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(20)34224.
    PubMed     Abstract available


  319. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    PubMed     Abstract available


  320. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    PubMed     Abstract available


  321. EOH KJ, Han M, Kim EH, Jung I, et al
    Markedly increased risk of malignancies in women with endometriosis.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00079.
    PubMed     Abstract available


  322. BOGANI G, Sopracordevole F, Di Donato V, Ciavattini A, et al
    High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00080.
    PubMed     Abstract available


  323. CHAMBERS LM, Michener CM, Rose PG, Reizes O, et al
    Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
    Gynecol Oncol. 2021 Jan 24. pii: S0090-8258(21)00075.
    PubMed     Abstract available


  324. BOGANI G, Papadia A, Buda A, Casarin J, et al
    Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study.
    Gynecol Oncol. 2021 Jan 20. pii: S0090-8258(21)00055.
    PubMed     Abstract available


  325. CHASE DM, Salani R, Farley J, Torres T, et al
    Unwittingly biased: A note to gynecologic cancer providers.
    Gynecol Oncol. 2021 Jan 20. pii: S0090-8258(21)00056.
    PubMed    


  326. KIM SR, Tone A, Kim RH, Cesari M, et al
    Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
    PubMed     Abstract available


  327. CHICHURA A, Chambers LM, Costales AB, Yao M, et al
    Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.
    Gynecol Oncol. 2021 Jan 16. pii: S0090-8258(21)00053.
    PubMed     Abstract available


  328. NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
    Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
    PubMed     Abstract available


  329. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    PubMed     Abstract available


  330. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    PubMed     Abstract available


  331. KALJOUW S, Jansen EEL, Aitken CA, Harrijvan LM, et al
    Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
    Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34253.
    PubMed     Abstract available


  332. HAMILTON CA, Pothuri B, Arend RC, Backes FJ, et al
    Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
    Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34227.
    PubMed     Abstract available


  333. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    PubMed     Abstract available


  334. KO EM, Aviles D, Koelper NC, Morgan MA, et al
    Impact of past surgical history on perioperative outcomes in gynecologic surgery.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34241.
    PubMed     Abstract available


  335. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    PubMed     Abstract available


  336. KANAO H, Aoki Y, Omi M, Nomura H, et al
    Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: Technical feasibility and short-term oncologic outcome.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34249.
    PubMed     Abstract available


  337. LEES B, Hampton JM, Trentham-Dietz A, Newcomb P, et al
    A population-based study of causes of death after endometrial cancer according to major risk factors.
    Gynecol Oncol. 2021 Jan 6. pii: S0090-8258(20)34223.
    PubMed     Abstract available


  338. MATSUZAKI S, Matsuzaki S, Chang EJ, Yasukawa M, et al
    Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34247.
    PubMed     Abstract available


  339. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    PubMed    


  340. ZAPARDIEL I, Kocian R, Kohler C, Klat J, et al
    Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34221.
    PubMed     Abstract available


  341. TJALSMA AS, Wagner A, Dinjens WNM, Ewing-Graham PC, et al
    Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34242.
    PubMed     Abstract available


  342. DI DONATO V, Caruso G, Bogani G, Giannini A, et al
    Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: A systematic review.
    Gynecol Oncol. 2021 Jan 4. pii: S0090-8258(20)34245.
    PubMed     Abstract available


  343. MATSUO K, Matsuzaki S, Mandelbaum RS, Kanao H, et al
    Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States.
    Gynecol Oncol. 2021 Jan 2. pii: S0090-8258(20)34251.
    PubMed     Abstract available


  344. BATMAN S, Bohn J, Weisenberger MW, Hersh A, et al
    Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
    Gynecol Oncol. 2021;160:214-218.
    PubMed     Abstract available


  345. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    PubMed     Abstract available


  346. SPINOSA D, Acosta T, Wong J, Kurtovic K, et al
    Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative.
    Gynecol Oncol. 2021;160:169-174.
    PubMed     Abstract available


  347. HAMPEL H, Pearlman R, de la Chapelle A, Pritchard CC, et al
    Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Gynecol Oncol. 2021;160:161-168.
    PubMed     Abstract available


  348. SHALOWITZ DI
    Physician outreach and access to gynecologic cancer care.
    Gynecol Oncol. 2021;160:1-2.
    PubMed    


  349. GOODMAN CD, Mendez LC, Velker V, Weiss Y, et al
    3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience.
    Gynecol Oncol. 2021;160:134-139.
    PubMed     Abstract available


  350. ALIMENA S, Sullivan MW, Philp L, Dorney K, et al
    Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship.
    Gynecol Oncol. 2021;160:252-259.
    PubMed     Abstract available


  351. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    PubMed     Abstract available


  352. VAN DER VELDEN J, Pleunis N, Barlow E, Zijlmans H, et al
    Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis.
    Gynecol Oncol. 2021;160:128-133.
    PubMed     Abstract available


  353. INAYAMA Y, Yamanishi Y, Nakatani E, Aratake J, et al
    Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis.
    Gynecol Oncol. 2021;160:140-147.
    PubMed     Abstract available


  354. BOGANI G, Raspagliesi F, di Donato V, Brusadelli C, et al
    Spotlight on the role of human papillomavirus vaccines.
    Gynecol Oncol. 2021;160:346-350.
    PubMed     Abstract available


    December 2020
  355. DAHLMAN D, Li X, Magnusson H, Sundquist J, et al
    Cervical cancer among Swedish women with drug use disorders: A nationwide epidemiological study.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34214.
    PubMed     Abstract available


  356. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    PubMed     Abstract available


  357. MOYNAGH MR, Dowdy SC, Welch B, Glaser GE, et al
    Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program.
    Gynecol Oncol. 2020 Dec 30. pii: S0090-8258(20)34252.
    PubMed     Abstract available


  358. BISCH SP, Jago CA, Kalogera E, Ganshorn H, et al
    Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 30. pii: S0090-8258(20)34250.
    PubMed     Abstract available


  359. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    PubMed     Abstract available


  360. MATSUO K, Nishio S, Matsuzaki S, Iwase H, et al
    Surgical margin status and recurrence pattern in invasive vulvar Paget's disease: A Japanese Gynecologic Oncology Group study.
    Gynecol Oncol. 2020 Dec 28. pii: S0090-8258(20)34226.
    PubMed     Abstract available


  361. MESSELT A, Thomaier L, Jewett PI, Lee H, et al
    Comparisons of emotional health by diagnosis among women with early stage gynecological cancers.
    Gynecol Oncol. 2020 Dec 28. pii: S0090-8258(20)34222.
    PubMed     Abstract available


  362. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    PubMed     Abstract available


  363. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    PubMed     Abstract available


  364. BERGER AA, Dao F, Levine DA
    Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34219.
    PubMed     Abstract available


  365. AYHAN A, Toptas T, Oz M, Vardar MA, et al
    Low-grade endometrial stromal sarcoma: A Turkish uterine sarcoma group study analyzing prognostic factors and disease outcomes.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34220.
    PubMed     Abstract available


  366. CASTELLANO T, John Maxwell IV, Adam Walter J, Thompson S, et al
    Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34217.
    PubMed     Abstract available


  367. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    PubMed     Abstract available


  368. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    PubMed     Abstract available


  369. JOU J, Coulter E, Roberts T, Binder P, et al
    Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34180.
    PubMed     Abstract available


  370. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    PubMed     Abstract available


  371. FACHINI AMD, Zuliani AC, Sarian LO, Teixeira JC, et al
    Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.
    Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34157.
    PubMed     Abstract available


  372. LEUNG E, Pervaiz Z, Lowe-Zinola J, Cree S, et al
    Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre.
    Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34216.
    PubMed     Abstract available


  373. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    PubMed     Abstract available


  374. FORD S, Tarraf W, Williams KP, Roman LA, et al
    Differences in cervical cancer screening and follow-up for black and white women in the United States.
    Gynecol Oncol. 2020 Dec 12. pii: S0090-8258(20)34155.
    PubMed     Abstract available


  375. FORSSE D, Berg HF, Bozickovic O, Engerud H, et al
    Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34173.
    PubMed     Abstract available


  376. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    PubMed     Abstract available


  377. COLLINS A, Miles GJ, Powley IR, Hew R, et al
    Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.
    Gynecol Oncol. 2020 Dec 10. pii: S0090-8258(20)34161.
    PubMed     Abstract available


  378. SOBECKI JN, Rice LW, Hartenbach EM
    Bone health and osteoporosis screening in gynecologic cancer survivors.
    Gynecol Oncol. 2020 Dec 10. pii: S0090-8258(20)34156.
    PubMed     Abstract available


  379. NAHSHON C, Segev Y, Gemer O, Bar Noy T, et al
    Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 9. pii: S0090-8258(20)34162.
    PubMed     Abstract available


  380. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    PubMed     Abstract available


  381. CAIN KE, Iniesta MD, Fellman BM, Suki TS, et al
    Effect of preoperative intravenous vs oral acetaminophen on postoperative opioid consumption in an enhanced recovery after surgery (ERAS) program in patients undergoing open gynecologic oncology surgery.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34152.
    PubMed     Abstract available


  382. PAREEK V, Barthwal M, Giridhar P, Patil PA, et al
    A phase III randomised trial of trans-abdominal ultrasound in improving application quality and dosimetry of intra-cavitary brachytherapy in locally advanced cervical cancer.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34160.
    PubMed     Abstract available


  383. APPIAH D, Farias RM, Olokede OA, Nwabuo CC, et al
    The influence of individual and neighborhood-level characteristics on rural-urban disparities in cardiovascular disease mortality among U.S. women diagnosed with breast and gynecologic cancers.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34151.
    PubMed     Abstract available


  384. NGO NT, Aniagolu N, Lang J, Mcdougale A, et al
    Underrepresented minority representation trends in gynecologic oncology fellowships in the United States.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34130.
    PubMed     Abstract available


  385. TRAVAGLINO A, Raffone A, Gencarelli A, Saracinelli S, et al
    Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34126.
    PubMed     Abstract available


  386. ISLAM JY, Deveaux A, Previs RA, Akinyemiju T, et al
    Racial and ethnic disparities in palliative care utilization among gynecological cancer patients.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34159.
    PubMed     Abstract available


  387. COHEN JG, Chang AJ
    Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications.
    Gynecol Oncol. 2020;159:599-600.
    PubMed    


  388. DEKEN MM, van Doorn HC, Verver D, Boogerd LSF, et al
    Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer - a randomized controlled trial.
    Gynecol Oncol. 2020;159:672-680.
    PubMed     Abstract available


  389. SPINILLO A, Dominoni M, Boschi AC, Cesari S, et al
    The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
    Gynecol Oncol. 2020;159:630-635.
    PubMed     Abstract available


  390. COHEN PA, Leung Y, Anderson L, van der Griend R, et al
    Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and
    Gynecol Oncol. 2020;159:623-629.
    PubMed     Abstract available


  391. HELLMAN K, Holmberg E, Bjurberg M, Borgfeldt C, et al
    Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study.
    Gynecol Oncol. 2020;159:663-671.
    PubMed     Abstract available


  392. RICHMAN AH, Vargo JA, Ling DC, Sukumvanich P, et al
    Dose-escalated intensity modulated radiation therapy in patients with locally-advanced vulvar cancer - does it increase response rate?
    Gynecol Oncol. 2020;159:657-662.
    PubMed     Abstract available


  393. BOGANI G, DI Donato V, Sopracordevole F, Ciavattini A, et al
    Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.
    Gynecol Oncol. 2020;159:636-641.
    PubMed     Abstract available


  394. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    PubMed     Abstract available


  395. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    PubMed     Abstract available


  396. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    PubMed     Abstract available


  397. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    PubMed     Abstract available


    November 2020
  398. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    PubMed     Abstract available


  399. SUGRUE R, Foley O, Elias KM, Growdon WB, et al
    Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34150.
    PubMed     Abstract available


  400. GRESSEL GM, Marcus JZ, Mullen MM, Sinno AK, et al
    Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement.
    Gynecol Oncol. 2020 Nov 28. pii: S0090-8258(20)34131.
    PubMed     Abstract available


  401. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    PubMed     Abstract available


  402. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    PubMed     Abstract available


  403. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    PubMed     Abstract available


  404. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    PubMed     Abstract available


  405. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    PubMed     Abstract available


  406. HICKS-COURANT K, Kanter GP, Giuntoli RL 2nd, Schapira MM, et al
    An increase in multi-site practices: The shifting paradigm for gynecologic cancer care delivery.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34052.
    PubMed     Abstract available


  407. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    PubMed     Abstract available


  408. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    PubMed     Abstract available


  409. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    PubMed     Abstract available


  410. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    PubMed     Abstract available


  411. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    PubMed     Abstract available


  412. RODRIGUEZ AM, Polychronopoulou E, Hsu E, Shah R, et al
    Factors associated with endometrial cancer and hyperplasia among middle-aged and older Hispanics.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34055.
    PubMed     Abstract available


  413. CHAMBERS LM, Jia X, Rose PG, AlHilli M, et al
    Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34123.
    PubMed     Abstract available


  414. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    PubMed     Abstract available


  415. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    PubMed     Abstract available


  416. AYHAN A, Oz M, Topfedaisi Ozkan N, Aslan K, et al
    Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34125.
    PubMed     Abstract available


  417. STALEY SA, Tucker KR, Gehrig PA, Clark LH, et al
    Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34067.
    PubMed     Abstract available


  418. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    PubMed     Abstract available


  419. HOEIJMAKERS YM, Gorris MAJ, Sweep FCGJ, Bulten J, et al
    Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34113.
    PubMed     Abstract available


  420. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    PubMed     Abstract available


  421. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    PubMed     Abstract available


  422. JANSEN EEL, Ivanus U, Jerman T, de Koning HJ, et al
    The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
    Gynecol Oncol. 2020 Nov 13. pii: S0090-8258(20)34058.
    PubMed     Abstract available


  423. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    PubMed     Abstract available


  424. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    PubMed     Abstract available


  425. GUO XM, Cowan M, Folsom S, Ehimiaghe E, et al
    Discrepancies between author- and industry-reported disclosures of financial relationships at an annual gynecologic oncology research meeting.
    Gynecol Oncol. 2020 Nov 10. pii: S0090-8258(20)34061.
    PubMed     Abstract available


  426. NITECKI R, Fu S, Lefkowits C, Smith BD, et al
    Employment disruption following the diagnosis of endometrial cancer.
    Gynecol Oncol. 2020 Nov 9. pii: S0090-8258(20)34063.
    PubMed     Abstract available


  427. MATSUZAKI S, Klar M, Matsuzaki S, Roman LD, et al
    Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
    Gynecol Oncol. 2020 Nov 9. pii: S0090-8258(20)34065.
    PubMed     Abstract available


  428. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    PubMed     Abstract available


  429. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    PubMed     Abstract available


  430. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    PubMed     Abstract available


  431. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    PubMed     Abstract available


  432. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    PubMed     Abstract available


  433. LEE EK, Fader AN, Santin AD, Liu JF, et al
    Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34039.
    PubMed     Abstract available


  434. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    PubMed     Abstract available


  435. RUSSO S, Walker JL, Carlson JW, Carter J, et al
    Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34048.
    PubMed     Abstract available


  436. PEDRA NOBRE S, Hensley ML, So M, Zhou QC, et al
    The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34042.
    PubMed     Abstract available


  437. DE LA MOTTE ROUGE T, Touboul C, Lhomel C, Roupret M, et al
    Factors associated with compliance to cervical cancer screening in France: The EDIFICE 6 survey.
    Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34054.
    PubMed     Abstract available


  438. BREWSTER WR
    Insurance and adherence to guideline concordant cervical cancer therapy do not reduce mortality?
    Gynecol Oncol. 2020;159:297-298.
    PubMed    


  439. YANG J, Delara R, Magrina J, Magtibay P, et al
    Management and outcomes of primary vaginal Cancer.
    Gynecol Oncol. 2020;159:456-463.
    PubMed     Abstract available


  440. BRZEZINSKA BN, Shepherd JP, Rath KS, Clements AE, et al
    A cost-effectiveness analysis of sentinel lymph node detection in vulvar cancer by preoperative lymphoscintigraphy versus intraoperative detection alone.
    Gynecol Oncol. 2020;159:498-502.
    PubMed     Abstract available


    October 2020
  441. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    PubMed     Abstract available


  442. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    PubMed     Abstract available


  443. JOU J, Binder P, Saenz C, Eskander R, et al
    Charting a professional course for academic gynecologic oncology mentors.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34046.
    PubMed     Abstract available


  444. CARTER J, Huang HQ, Armer J, Carlson JW, et al
    GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.
    Gynecol Oncol. 2020 Oct 24. pii: S0090-8258(20)34045.
    PubMed     Abstract available


  445. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    PubMed     Abstract available


  446. STINTON C, Fraser H, Al-Khudairy L, Court R, et al
    Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34011.
    PubMed     Abstract available


  447. HAN X, Liu S, Yang G, Hosseinifard H, et al
    Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
    Gynecol Oncol. 2020 Oct 19. pii: S0090-8258(20)34019.
    PubMed     Abstract available


  448. HUNG P, Zahnd WE, Brandt HM, Adams SA, et al
    Cervical cancer treatment initiation and survival: The role of residential proximity to cancer care.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34014.
    PubMed     Abstract available


  449. LI Q, Cong R, Wang Y, Kong F, et al
    Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34021.
    PubMed     Abstract available


  450. FERRISS JS, Rose S, Rungruang B, Urban R, et al
    Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34017.
    PubMed     Abstract available


  451. SAMOIL D, Abdelmutti N, Gallagher LO, Jivraj N, et al
    Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34015.
    PubMed     Abstract available


  452. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    PubMed     Abstract available


  453. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    PubMed     Abstract available


  454. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    PubMed     Abstract available


  455. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    PubMed     Abstract available


  456. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    PubMed     Abstract available


  457. RESHKO LB, Baliga S, Crandley EF, Harry Lomas IV, et al
    Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33967.
    PubMed     Abstract available


  458. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    PubMed     Abstract available


  459. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    PubMed     Abstract available


  460. KWON BS, Roh HJ, Lee S, Yang J, et al
    Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.
    Gynecol Oncol. 2020 Oct 8. pii: S0090-8258(20)33945.
    PubMed     Abstract available


  461. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    PubMed     Abstract available


  462. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    PubMed     Abstract available


  463. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    PubMed     Abstract available


  464. JAREEMIT N, Horowitz NS, Goldstein DP, Berkowitz RS, et al
    Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
    Gynecol Oncol. 2020 Oct 3. pii: S0090-8258(20)33956.
    PubMed     Abstract available


  465. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    PubMed    


  466. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    Using machine learning to create prognostic systems for endometrial cancer.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33957.
    PubMed     Abstract available


  467. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    PubMed     Abstract available


  468. ROSSI EC
    Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.
    Gynecol Oncol. 2020;159:1-2.
    PubMed    


  469. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    PubMed     Abstract available


  470. HUH WK
    51st Annual Meeting of the Society of Gynecologic Oncology.
    Gynecol Oncol. 2020;159 Suppl 1:1.
    PubMed    


  471. BAO H, Bi H, Zhang X, Zhao Y, et al
    Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study.
    Gynecol Oncol. 2020;159:171-178.
    PubMed     Abstract available


  472. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    PubMed     Abstract available


  473. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    PubMed    


  474. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    PubMed     Abstract available


    September 2020
  475. CYR MP, Dumoulin C, Bessette P, Pina A, et al
    Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33856.
    PubMed     Abstract available


  476. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    PubMed     Abstract available


  477. CHEN LC, Huang Y, Hou JY, Khoury-Collado F, et al
    Toxicity after adjuvant therapy for stage III uterine cancer.
    Gynecol Oncol. 2020 Sep 29. pii: S0090-8258(20)33943.
    PubMed     Abstract available


  478. STENZEL AE, Moysich KB, Ferrando CA, Starbuck KD, et al
    Clinical needs for transgender men in the gynecologic oncology setting.
    Gynecol Oncol. 2020 Sep 29. pii: S0090-8258(20)33948.
    PubMed     Abstract available


  479. NASIOUDIS D, Albright BB, Roy A, Ko EM, et al
    Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer.
    Gynecol Oncol. 2020 Sep 28. pii: S0090-8258(20)33916.
    PubMed    


  480. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    PubMed    


  481. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    PubMed     Abstract available


  482. ROMERO I, Rubio MJ, Medina M, Matias-Guiu X, et al
    An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Gynecol Oncol. 2020 Sep 25. pii: S0090-8258(20)33906.
    PubMed     Abstract available


  483. SMITH M, Lara OD, O'Cearbhaill R, Knisely A, et al
    Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection.
    Gynecol Oncol. 2020 Sep 25. pii: S0090-8258(20)33946.
    PubMed     Abstract available


  484. ALBRIGHT BB, Nasioudis D, Byrne ME, Latif NA, et al
    Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33942.
    PubMed     Abstract available


  485. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    PubMed     Abstract available


  486. FREY MK, Fowlkes RK, Badiner NM, Fishman D, et al
    Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33898.
    PubMed     Abstract available


  487. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    PubMed     Abstract available


  488. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    PubMed     Abstract available


  489. PERRONE AM, Dondi G, Giunchi S, De Crescenzo E, et al
    COVID-19 free oncologic surgical hub: The experience of reallocation of a gynecologic oncology unit during pandemic outbreak.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33940.
    PubMed     Abstract available


  490. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    PubMed     Abstract available


  491. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    PubMed     Abstract available


  492. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33850.
    PubMed     Abstract available


  493. CHINO J, Annunziata CM, Beriwal S, Bradfield L, et al
    The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33908.
    PubMed    


  494. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    PubMed     Abstract available


  495. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    PubMed     Abstract available


  496. KORTEKAAS KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, et al
    Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33917.
    PubMed     Abstract available


  497. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
    PubMed     Abstract available


  498. GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
    The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
    PubMed     Abstract available


  499. RIEDINGER CJ, Kimball KJ, Kilgore LC, Bell CW, et al
    Water only fasting and its effect on chemotherapy administration in gynecologic malignancies.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33901.
    PubMed     Abstract available


  500. MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
    Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
    PubMed     Abstract available


  501. KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
    Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
    PubMed     Abstract available


  502. JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
    mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
    PubMed     Abstract available


  503. BOITANO TKL, Sanders LJ, Gentry ZL, Smith HJ, et al
    Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33907.
    PubMed     Abstract available


  504. YOSHIMOTO Y, Sasaki Y, Murata K, Noda SE, et al
    Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33821.
    PubMed     Abstract available


  505. CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
    Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
    PubMed     Abstract available


  506. PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
    Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
    PubMed     Abstract available


  507. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    PubMed     Abstract available


  508. ZEIMET AG
    Molecular characterization of vulvar squamous cell cancer: High time to gain ground.
    Gynecol Oncol. 2020;158:519-520.
    PubMed    


  509. YANG J, Delara R, Ghaith S, Newman H, et al
    Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2020;158:555-561.
    PubMed     Abstract available


  510. PRIESKE K, Alawi M, Oliveira-Ferrer L, Jaeger A, et al
    Genomic characterization of vulvar squamous cell carcinoma.
    Gynecol Oncol. 2020;158:547-554.
    PubMed     Abstract available


  511. CAO D, Shen K, Chen Y, Xu Y, et al
    Value of endocervical curettage in follow-up for patients with cervical intraepithelial neoplasia stage 2+ after loop electrosurgical excision.
    Gynecol Oncol. 2020;158:584-589.
    PubMed     Abstract available


  512. BERTOLI HK, Baandrup L, Aalborg GL, Kjaer AK, et al
    Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study.
    Gynecol Oncol. 2020;158:734-739.
    PubMed     Abstract available


  513. FRUMOVITZ M, Westin SN, Salvo G, Zarifa A, et al
    Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
    Gynecol Oncol. 2020;158:570-575.
    PubMed     Abstract available


    August 2020
  514. ZIEBA S, Chechlinska M, Kowalik A, Kowalewska M, et al
    Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies.
    Gynecol Oncol. 2020;158:498-506.
    PubMed     Abstract available


    June 2020
  515. VASSEUR D, Lopez J, Croce S, Tondeur G, et al
    Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression.
    Gynecol Oncol. 2020;157:775-782.
    PubMed     Abstract available


  516. MANCINI S, Bucchi L, Baldacchini F, Giuliani O, et al
    Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015.
    Gynecol Oncol. 2020;157:656-663.
    PubMed     Abstract available


  517. KILTS TP, Long B, Glasgow AE, Bakkum-Gamez JN, et al
    Invasive vulvar extramammary Paget's disease in the United States.
    Gynecol Oncol. 2020;157:649-655.
    PubMed     Abstract available


  518. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    PubMed     Abstract available


  519. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    PubMed     Abstract available


  520. SPEKREIJSE JJ, Streng BMM, Vermeulen RFM, Voss FO, et al
    The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: A systematic review.
    Gynecol Oncol. 2020;157:671-677.
    PubMed     Abstract available


    May 2020
  521. PATEL SN, Staples JN, Garcia C, Chatfield L, et al
    Are ethnic and racial minority women less likely to participate in clinical trials?
    Gynecol Oncol. 2020;157:323-328.
    PubMed     Abstract available


  522. STUEBS FA, Mehlhorn G, Gass P, Schulmeyer CE, et al
    Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia.
    Gynecol Oncol. 2020;157:463-468.
    PubMed     Abstract available


  523. POUNDS R, O'Neill D, Subba K, Garg A, et al
    The role of preoperative computerized tomography (CT) scan of the pelvis and groin in the management of clinically early staged vulva squamous cell carcinoma.
    Gynecol Oncol. 2020;157:444-449.
    PubMed     Abstract available


    April 2020
  524. GULTEKIN M, Dundar S, Keskinkilic B, Turkyilmaz M, et al
    How to triage HPV positive cases: Results of four million females.
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31008.
    PubMed     Abstract available


  525. REICH O, Regauer S, Kashofer K
    Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30985.
    PubMed     Abstract available


  526. RASMUSSEN CL, Thomsen LT, Aalborg GL, Kjaer SK, et al
    Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30255.
    PubMed     Abstract available


  527. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    PubMed     Abstract available


  528. GAULIN NB, Lesnock JL, Tian C, Osei-Bonsu K, et al
    Survival disparities in vulvar cancer patients in Commission on Cancer(R)-accredited facilities.
    Gynecol Oncol. 2020;157:136-145.
    PubMed     Abstract available


  529. NASIOUDIS D, Bhadra M, Ko EM
    Extramammary Paget disease of the vulva: Management and prognosis.
    Gynecol Oncol. 2020;157:146-150.
    PubMed     Abstract available


    February 2020
  530. EVA LJ, Sadler L, Fong KL, Sahota S, et al
    Trends in HPV-dependent and HPV-independent vulvar cancers: The changing face of vulvar squamous cell carcinoma.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30083.
    PubMed     Abstract available


    January 2020
  531. BERTOLI HK, Thomsen LT, Iftner T, Dehlendorff C, et al
    Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30082.
    PubMed     Abstract available


  532. LI T, Wu Z, Jiang M, Zhao Y, et al
    Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.
    Gynecol Oncol. 2020 Jan 18. pii: S0090-8258(20)30022.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: